Germany, FranceGermany

Sartorius Stedim Biotech rocks single-use bioreactor market


Aubagne/Frankfurt – Sartorius Stedim Biotech SA has substantially expanded its technology portfolio as a supplier for the bio-pharmaceutical industry. At the ACHEMA, the world´s largest trade fair for bioprocess equipment, the company presented two new prototypes of single-use bioreactors that make use of novel mixing technologies co-developed with Bayer Technology Services GmbH (BTS) and Swiss ExcellGene SA. The disposable systems are a major driver of growth for suppliers of the biopharmaceutical industry, because they offer cheaper and more flexible production possibilties than stainless steel fermentors that need time-consuming and expensive cleaning validation.
With the new bioreactors, which are specially designed for the manufacture of monoclonal antibodies, recombinant proteins and vaccines, Sartorius attacks competitors like Thermo Fisher, who offer single use stirred bioreactors or GE Healthcare, who markets shaked reusable plastic bags for mid-scale biomanufacture.
„Based on this comprehensive technology platform, we are taking a huge step forward towards achieving our goal of becoming the global market leader in single-use bioreactors," said Dr. Oscar-Werner Reif, Member of Sartorius Stedim Biotech's Board of Directors.
From 2010, the company plans to extend its technology portfolio, which already comprises stirred and shaked bioreactor types, by the novel systems. The rotationally oscillating bioreactor, co-developed with Bayer Schering Pharma AG, allows for surface or membrane gasing of sensitive cultures. The orbital shake bioreactor, developed with ExcellGene, allows for screening of media and cultivation conditions. Each of the four agitation technologies offers user specific advantages contingent upon the cells to be produced, the scale-up level of the cell cultures and additional process parameters. Despite financial crisis, ACHEMA achieved its second best result ever, regarding the number of exhibitors.

Germany, FranceGermany


Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...



Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...



Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...



Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...



While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...



Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...



Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....



Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • CYTOS0.66 CHF6.45%
  • EVOLVA1.84 CHF5.14%
  • EPIGENOMICS5.55 EUR4.52%


  • MEDIGENE8.43 EUR-3.77%
  • WILEX3.95 EUR-2.47%
  • BASILEA132.00 CHF-2.08%


  • 4SC4.65 EUR257.7%
  • SYNGENTA430.80 CHF31.8%
  • EVOLVA1.84 CHF21.1%


  • CYTOS0.66 CHF-35.3%
  • MEDIGENE8.43 EUR-30.7%
  • CO.DON2.85 EUR-17.4%


  • WILEX3.95 EUR393.7%
  • 4SC4.65 EUR322.7%
  • FORMYCON28.39 EUR311.4%


  • MOLOGEN5.05 EUR-53.4%
  • BIOFRONTERA2.29 EUR-24.9%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.05.2015

Current issue

All issues